© 2021 MJH Life Sciences™ , Dermatology Times and Multimedia Medical, LLC. All rights reserved.
Chicago - Among patients receiving a novel immune-based maintenance biotherapy regimen (mBT) for metastatic melanoma, those who developed vitiligo had longer median survival.